Development of a unique Bismuth (Bi-213) automated generator for use in cancer therapy.

被引：0
|
作者：
Bray, LA [1 ]
Tingey, JM [1 ]
DesChane, JR [1 ]
Egorov, OB [1 ]
机构：
[1] Pacific NW Natl Lab, Richland, WA USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 1998年 / 216卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
049-IEC
引用
收藏
页码：U927 / U927
页数：1
相关论文
共 50 条
  • [31] Abemaciclib, a CDK4 and 6 inhibitor with unique pharmacological properties for breast cancer therapy.
    Torres-Guzman, Raquel
    Ganado, Maria Patricia
    Perez, Cecila Mur
    Marugan, Carlos
    Baquero, Carmen
    Yang, Yanzhu
    Du, Jian
    de Dios, Alfonso
    Puig, Oscar
    Lallena, Maria Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Targeted alpha-therapy using [Bi-213] anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells
    Roscher, Mareike
    Hormann, Inis
    Leib, Oliver
    Marx, Sebastian
    Moreno, Josue
    Miltner, Erich
    Friesen, Claudia
    ONCOTARGET, 2013, 4 (02) : 218 - 230
  • [33] An alpha-particle emitting radiopeptide (213Bi-DOTA-PESIN) for therapy of prostate cancer
    Wild, Damian
    Frischknecht, Michael
    Morgenstern, Alfred
    Bruchertseifer, Frank
    Boisclair, Julie
    Provencher-Bolliger, Anne
    Maecke, Helmut
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [34] 213Bi-labeled PSMA-targeting agents for alpha radionuclide therapy of prostate cancer
    Chatalic, Kristell
    Nonnekens, Julie
    Bruchertseifer, Frank
    Morgenstern, Alfred
    Schottelius, Margret
    Wester, Hans
    van Weerden, Wytske
    Boerman, Otto
    de Jong, Marion
    Heskamp, Sandra
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [35] Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for chemo- and radioresistant non-Hodgkin's lymphoma cells
    Roscher, M.
    Hormann, I.
    Moreno, J.
    Leib, O.
    Marx, S.
    Miltner, E.
    Friesen, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S213 - S214
  • [36] Successful use of buprenorphine/naloxone to treat opioid addiction after cancer therapy.
    Moryl, Natalie
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07)
  • [37] In Vitro Cytotoxicity of Bismuth-213 (213bi)-Labeled-Plasminogen Activator Inhibitor Type 2 (Alpha-PAI-2) on Human Breast Cancer Cells
    M. Ranson
    Z. Tian
    N.M. Andronicos
    S. Rizvi
    B.J. Allen
    Breast Cancer Research and Treatment, 2002, 71 : 149 - 159
  • [38] Growth factor use and costs in breast cancer patients undergoing adjuvant therapy.
    Noh, Hyun Gi
    Paramanathan, Dhakshila
    Suryadevara, Kiran
    Choi, Kelly
    Smith, Augie
    Kea, William
    Schultz, Eric V.
    Pecora, Andrew
    Goldberg, Stuart L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells
    Ranson, M
    Tian, Z
    Andronicos, NM
    Rizvi, S
    Allen, BJ
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 71 (02) : 149 - 159
  • [40] Biodistribution of Actinium-225 (Ac-225) and Bismuth-213 (Bi-213) in the kidney and liver in Ac-225 labeled PSMA and octreotate (DOTA TATE) treatment and the effect of 2,3-Dimercapto-1-propanesulfonic acid (DMPS) on biodistribution.
    Karayel, E.
    Pehlivanoglu, H.
    Kibar, A.
    Yeyin, N.
    Onenerk, A. M.
    Kalaycilar, I. B.
    Toklu, T.
    Ocak, E. M.
    Demirci, E.
    Selcuk, N. Alan
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S797 - S797
12345